Cargando…

Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy

PURPOSE: The body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Takada, Koji, Kashiwagi, Shinichiro, Asano, Yuka, Goto, Wataru, Ishihara, Sae, Morisaki, Tamami, Shibutani, Masatsune, Tanaka, Hiroaki, Hirakawa, Kosei, Ohira, Masaichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529767/
https://www.ncbi.nlm.nih.gov/pubmed/34670511
http://dx.doi.org/10.1186/s12885-021-08857-7
_version_ 1784586535820066816
author Takada, Koji
Kashiwagi, Shinichiro
Asano, Yuka
Goto, Wataru
Ishihara, Sae
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Hirakawa, Kosei
Ohira, Masaichi
author_facet Takada, Koji
Kashiwagi, Shinichiro
Asano, Yuka
Goto, Wataru
Ishihara, Sae
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Hirakawa, Kosei
Ohira, Masaichi
author_sort Takada, Koji
collection PubMed
description PURPOSE: The body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes present in the vicinity of malignant growths that are involved in the tumors’ immune responses influence the efficacy chemotherapy. Therefore, we hypothesized that OB patients with breast cancer have a lower density of tumor-infiltrating lymphocytes (TILs), which may influence the therapeutic effect of preoperative chemotherapy (POC). In this study, we measured pretreatment BMI and TILs in patients with breast cancer who underwent POC, examined the correlations between these two factors, and retrospectively analyzed their therapeutic outcomes and prognoses. METHODS: The participants in this study were 421 patients with breast cancer who underwent surgical treatment after POC between February 2007 and January 2019. The patient’s height and weight were measured before POC to calculate the BMI (weight [kg] divided by the square of the height [m(2)]). According to the World Health Organization categorization, patients who weighed under 18.5 kg/m(2) were classified as underweight (UW), those ≥18.5 kg/m(2) and > 25 kg/m(2) were considered normal weight (NW), those ≥25 kg/m(2) and < 30 kg/m(2) were overweight (OW), and those ≥30 kg/m(2) were OB. The TILs were those lymphocytes that infiltrated the tumor stroma according to the definition of the International TILs Working Group 2014. RESULTS: The median BMI was 21.9 kg/m(2) (range, 14.3–38.5 kg/m(2)); most patients (244; 64.5%) were NW. Among all 378 patients with breast cancer, the TIL density was significantly lower in OB than in NW and OW patients (vs. NW: p = 0.001; vs. OW: p = 0.003). Furthermore, when examining patients with each breast cancer type individually, the OS of those with TNBC who had low BMIs was significantly poorer than that of their high-BMI counterparts (log rank p = 0.031). CONCLUSIONS: Our data did not support the hypothesis that obesity affects the tumor immune microenvironment; however, we showed that being UW does affect the tumor immune microenvironment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08857-7.
format Online
Article
Text
id pubmed-8529767
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85297672021-10-25 Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy Takada, Koji Kashiwagi, Shinichiro Asano, Yuka Goto, Wataru Ishihara, Sae Morisaki, Tamami Shibutani, Masatsune Tanaka, Hiroaki Hirakawa, Kosei Ohira, Masaichi BMC Cancer Research PURPOSE: The body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes present in the vicinity of malignant growths that are involved in the tumors’ immune responses influence the efficacy chemotherapy. Therefore, we hypothesized that OB patients with breast cancer have a lower density of tumor-infiltrating lymphocytes (TILs), which may influence the therapeutic effect of preoperative chemotherapy (POC). In this study, we measured pretreatment BMI and TILs in patients with breast cancer who underwent POC, examined the correlations between these two factors, and retrospectively analyzed their therapeutic outcomes and prognoses. METHODS: The participants in this study were 421 patients with breast cancer who underwent surgical treatment after POC between February 2007 and January 2019. The patient’s height and weight were measured before POC to calculate the BMI (weight [kg] divided by the square of the height [m(2)]). According to the World Health Organization categorization, patients who weighed under 18.5 kg/m(2) were classified as underweight (UW), those ≥18.5 kg/m(2) and > 25 kg/m(2) were considered normal weight (NW), those ≥25 kg/m(2) and < 30 kg/m(2) were overweight (OW), and those ≥30 kg/m(2) were OB. The TILs were those lymphocytes that infiltrated the tumor stroma according to the definition of the International TILs Working Group 2014. RESULTS: The median BMI was 21.9 kg/m(2) (range, 14.3–38.5 kg/m(2)); most patients (244; 64.5%) were NW. Among all 378 patients with breast cancer, the TIL density was significantly lower in OB than in NW and OW patients (vs. NW: p = 0.001; vs. OW: p = 0.003). Furthermore, when examining patients with each breast cancer type individually, the OS of those with TNBC who had low BMIs was significantly poorer than that of their high-BMI counterparts (log rank p = 0.031). CONCLUSIONS: Our data did not support the hypothesis that obesity affects the tumor immune microenvironment; however, we showed that being UW does affect the tumor immune microenvironment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08857-7. BioMed Central 2021-10-20 /pmc/articles/PMC8529767/ /pubmed/34670511 http://dx.doi.org/10.1186/s12885-021-08857-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Takada, Koji
Kashiwagi, Shinichiro
Asano, Yuka
Goto, Wataru
Ishihara, Sae
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Hirakawa, Kosei
Ohira, Masaichi
Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
title Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
title_full Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
title_fullStr Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
title_full_unstemmed Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
title_short Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
title_sort clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529767/
https://www.ncbi.nlm.nih.gov/pubmed/34670511
http://dx.doi.org/10.1186/s12885-021-08857-7
work_keys_str_mv AT takadakoji clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy
AT kashiwagishinichiro clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy
AT asanoyuka clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy
AT gotowataru clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy
AT ishiharasae clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy
AT morisakitamami clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy
AT shibutanimasatsune clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy
AT tanakahiroaki clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy
AT hirakawakosei clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy
AT ohiramasaichi clinicalverificationofbodymassindexandtumorimmuneresponseinpatientswithbreastcancerreceivingpreoperativechemotherapy